What Is Ibogaine?
Ibogaine is a naturally occurring psychoactive alkaloid found in the root bark of the African shrub Tabernanthe iboga. It has been used for centuries in Bwiti spiritual traditions in Central Africa, particularly in Gabon and Cameroon. In modern contexts, ibogaine has gained attention primarily for its potential to interrupt opioid and other substance addictions.
Unlike classical psychedelics, ibogaine produces an extended experience lasting 24-72 hours with distinct phases: an acute visionary phase, an introspective/processing phase, and a residual stimulation phase. It acts on multiple neurotransmitter systems simultaneously, including serotonin, dopamine, opioid, and NMDA receptors.
Dosage Levels
Ibogaine dosing is calculated by body weight in milligrams per kilogram (mg/kg). This is critical because ibogaine has a narrow therapeutic window — the difference between an effective dose and a dangerous dose is small. All dosages below refer to ibogaine HCl (hydrochloride), the most common purified form.
Microdose
1–5 mg/kg ibogaine HCl
Sub-psychoactive doses used in some therapeutic contexts for mood support, energy, and to reduce cravings over time. Effects are subtle and may include mild stimulation, increased alertness, and slight mood elevation. Some practitioners use a "boosting" protocol with repeated low doses.
Flood Dose
10–25 mg/kg ibogaine HCl
The full "flood dose" is used in addiction interruption treatment. It produces a powerful, extended psychedelic experience lasting 24-72 hours. This dose range is where ibogaine's anti-addictive properties are most pronounced — and where the cardiac risks are highest.
MEDICAL SUPERVISION ONLY. Flood doses must only be administered in a clinical setting with cardiac monitoring (continuous EKG), emergency resuscitation equipment, and trained medical staff. Fatalities have occurred at these doses.
Timeline & Phases
A flood dose experience unfolds in three distinct phases over an extended period:
Phase 1: Acute / Visionary (4–8 hours)
Onset begins 45 minutes to 2 hours after oral ingestion. Intense, dreamlike visions often described as watching a panoramic movie of one's life. Strong ataxia (loss of motor coordination), nausea, and sensitivity to light and sound. Most individuals remain lying down with eyes closed.
Phase 2: Introspective / Processing (8–20 hours)
The visual intensity fades and is replaced by deep emotional processing and reflection. Many individuals report profound insights into behavioral patterns, trauma, and the roots of their addiction. Residual cognitive effects and emotional sensitivity persist.
Phase 3: Residual Stimulation (24–72 hours)
Difficulty sleeping is common for 24-72 hours after a flood dose due to ibogaine's stimulant properties. Noribogaine, ibogaine's active metabolite, remains in the body for weeks and is believed to contribute to sustained anti-addictive effects. Gradual return to baseline.
Cardiac Risks & Required Screening
The primary cause of ibogaine-related deaths is cardiac arrhythmia, specifically due to QT interval prolongation. Ibogaine blocks hERG potassium channels in the heart, which can lead to a life-threatening condition called Torsades de Pointes (a type of ventricular tachycardia).
Mandatory Pre-Screening
- 1.12-lead EKG/ECG — QTc interval must be within normal range (under 450ms for men, 470ms for women)
- 2.Liver function panel — Ibogaine is metabolized by the liver; compromised liver function increases toxicity risk
- 3.Kidney function panel — Renal impairment affects drug clearance and metabolite accumulation
- 4.Complete blood panel — Check electrolytes (especially potassium and magnesium), which affect cardiac rhythm
- 5.Full cardiac history review — Any history of arrhythmia, heart disease, or fainting episodes is disqualifying
- 6.Medication review — Many common medications interact dangerously with ibogaine
Contraindicated Medications
The following medications and substances are strictly contraindicated with ibogaine due to dangerous or fatal interactions. All must be discontinued well before treatment under medical guidance:
- Methadone — Causes severe QT prolongation; must be tapered off weeks in advance
- SSRIs & SNRIs — Risk of serotonin syndrome; require 2-6 week washout
- Antipsychotics — Many prolong QT interval and compound cardiac risk
- Benzodiazepines — Respiratory depression risk; require medical taper
- Stimulants (cocaine, amphetamines) — Increased cardiac strain
- Anti-arrhythmic drugs — Compounding QT prolongation effects
- Certain antibiotics (fluoroquinolones, macrolides) — QT prolongation
- Alcohol — Liver toxicity and cardiovascular stress
- Grapefruit juice — Inhibits CYP2D6 enzyme responsible for ibogaine metabolism
This is not an exhaustive list. A full medication reconciliation by a qualified physician is essential before any ibogaine treatment.
Addiction Treatment Context
Ibogaine's primary modern use is in the treatment of opioid dependence. Research and clinical experience suggest that a single flood dose can significantly reduce or eliminate withdrawal symptoms and cravings, sometimes for weeks or months. This "interruption" effect is attributed to:
- Neuroplasticity — Ibogaine and its metabolite noribogaine promote the growth of new neural connections
- Opioid receptor reset — Ibogaine appears to reset the sensitivity of opioid receptors
- GDNF upregulation — Glial cell-derived neurotrophic factor promotes dopamine neuron health
- Psychological processing — The visionary experience often reveals emotional roots of addiction
However, ibogaine is not a "magic cure." Follow-up therapy, community support, and lifestyle changes are essential for sustained recovery. Relapse rates remain significant without comprehensive aftercare programs.
Safety Requirements
- 1.Never use alone — Ibogaine must only be administered with trained medical staff present for the entire experience
- 2.Continuous cardiac monitoring — EKG monitoring throughout the acute phase (minimum 24 hours)
- 3.Emergency equipment — Defibrillator, IV access, and resuscitation medications must be immediately available
- 4.Complete pre-screening — Full cardiac, liver, and kidney function tests within 30 days of treatment
- 5.Medication washout — All contraindicated medications must be properly tapered under medical supervision
- 6.Hydration and electrolytes — Maintain proper electrolyte balance before, during, and after treatment
- 7.Post-treatment monitoring — Medical observation for at least 48-72 hours following a flood dose
Who Should NOT Use Ibogaine
Ibogaine is contraindicated for individuals with:
- Any cardiac condition, arrhythmia, or prolonged QT interval
- Liver disease or impaired hepatic function
- Kidney disease or impaired renal function
- Seizure disorders or epilepsy
- History of stroke or cerebellar dysfunction
- Pregnancy or breastfeeding
- Active psychosis or schizophrenia
- Current use of methadone (requires extended taper)
- Current use of SSRIs, SNRIs, or MAOIs
- Blood pressure abnormalities
- Electrolyte imbalances (low potassium or magnesium)
Legal Status
Ibogaine's legal status varies worldwide:
- United States — Schedule I controlled substance (illegal)
- Canada — Not approved but available through Special Access Programme
- Mexico — Unregulated; many treatment clinics operate here
- Brazil — Legal and used in some treatment facilities
- New Zealand — Available by prescription
- Most of Europe — Varies by country; unregulated in some, controlled in others
- Gabon — Declared a national treasure; legal for traditional use
Many individuals seeking ibogaine treatment travel to countries where it is legal or unregulated. When choosing a clinic, verify their medical credentials, cardiac monitoring capabilities, and emergency protocols. The absence of regulation means quality and safety standards vary dramatically.
Our Position
Ibogaine represents one of the most promising — and most dangerous — tools in the psychedelic medicine landscape. Its potential to interrupt severe addiction is remarkable, but the cardiac risks are real and documented. We strongly emphasize that ibogaine should only ever be considered in a fully equipped clinical setting with comprehensive medical screening. If you or someone you know is considering ibogaine treatment for addiction, research clinics thoroughly and prioritize those with full cardiac monitoring, licensed medical staff, and established emergency protocols.
Continue Learning
This guide is one part of our comprehensive education library. Explore our other dosing guides for Psilocybin, LSD, DMT, and Ketamine. You can also visit our Harm Reduction Basics article, browse our Strain Library, or check our Education Hub for guides and definitions.